OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Hematology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review	50
Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma	45
COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis	42
Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma	41
Advances in myelodysplastic syndromes: promising novel agents and combination strategies	32
The National Hemophilia Foundation State of the Science Research Summit initiative: executive summary	28
Hematological parameters and X-ray exposure among medical radiation workers: a systematic review and meta-analysis	23
Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms	22
A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly	22
Post-COVID-19 hematologic complications: a systematic review	20
An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: ‘bridging the gap between laboratory data and patient related outcomes’	20
Synovitis in hemophilia: preventing, detecting, and treating joint bleeds	20
Exploring health disparities in diagnosing multiple myeloma	19
The promise of novel treatments for severe chronic neutropenia	18
Bridging the gap: how do we enroll more racial-ethnic minority patients in hematological drug trials?	17
Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection	16
Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review	15
Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura	15
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia	14
Genetic variant of endothelial protein C receptor genes and its serum level in B thalassemic children	14
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care	13
Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts	13
An update on the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura	13
Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia	12
Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?	12

Recent advances in therapeutic options for rare hemostatic disorders: selected poster extracts of recent research in hemophilia A, congenital hemophilia with inhibitors, von Willebrand disease, and th	12
Frequencies of glycosylphosphatidylinositol (GPI)-deficient cells using high-sensitivity flow cytometry as per the 2018 ICCS/ESCCA consensus guideline in patients with hematologic malignancy, aplastic	11
Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria	11
Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP	11
Exploring shared pathogenesis of multiple myeloma and osteoporosis via bioinformatic analysis	11
Cyclophosphamide and horse anti-thymocyte globulin versus fludarabine, reduced cyclophosphamide and rabbit anti-thymocyte globulin conditioning regimen for allogeneic hematopoietic stem cell transplan	10
Factors associated with blood pressure variation in sickle cell disease patients: a systematic review and meta-analyses	10
Curative effect of motherwort combined with ethinylestradiol-cyproterone acetate on dysfunctional uterine bleeding	10
Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies	10
How low risk are low risk myelodysplastic syndromes?	10
Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis	10
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia	10
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide	10
Are we closer to a standard of care for Richter’s syndrome? Novel treatments on the horizon	10
CD123-targeted therapy in acute myeloid leukemia	9
Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura	9
Current therapies for chronic lymphocytic leukemia: risk and prophylaxis strategies for secondary/opportunistic infections	9
Inhibitor eradication and treatment for acquired hemophilia A	9
Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases	9
The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma	9
Do we need more guidance on thrombophilia testing? Challenges and special considerations	9
Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia	9
An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis	9
Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis	9
Improving care for systemic light-chain amyloidosis patients: is a multidisciplinary approach best?	8
Novel treatments for immune thrombocytopenia: targeting platelet autoantibodies	8
Computational modeling – an approach to the development of blood grouping reagents	8
What is the future of digital tools to help manage pain in sickle cell disease patients?	8
Cytomegalovirus induced hemophagocytic lymphohistiocytosis: diagnostic and treatment challenges for the future	8
Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances	8
Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management	8
Effect of days of age at first blood transfusion on intraventricular hemorrhage in very low and extremely low birth weight infants	8
Evolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemia	8
Next generation anticoagulants: a spotlight on the potential role of activated factors XII and XI	7
BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events	7
CRISPR-based gene therapy for the induction of fetal hemoglobin in sickle cell disease	7
Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies	7
Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis	7
Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women	7
The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease	7
Hairy cell leukemia (HCL) and HCL-like disorders: present, emergent treatment options and future directions	7
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera	7
Presentations and outcomes among sickle cell disease patients with COVID-19 at a large southern healthcare system	7
National strategic advocacy to manage patients with inherited bleeding disorders in low and lower-middle income countries	7
Applications of artificial intelligence to myeloproliferative neoplasms: a narrative review	7
Hemophagocytic lymphohistiocytosis in Egyptian children: diagnosis, treatment challenges, and outcome	7
The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas	7
The development of a home-based therapeutic platform for multiple myeloma	7
Robustness and pragmatism of the evidence supporting the European Society for Medical Oncology guidelines for the diagnosis, treatment, and follow-up of follicular lymphoma	6
Past, present, and future of orthopedic surgery in hemophilia: looking to a world without bleeding and arthropathy in the near future	6

Fetal anemia in monochorionic twins: a review on diagnosis, management, and outcome	6
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients	6
Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations	6
Is intensive chemotherapy and allogeneic stem cell transplantation mandatory for curing Philadelphia chromosome-positive acute lymphoblastic leukemia in young patients in the era of multitarget agents	6
Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them	6
Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma	6
Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients	5
Identifying prognostic gene panels in acute myeloid leukemia	5
Identification of miR-451 target genes as prognostic markers in diffuse large B-cell lymphoma	5
Emerging small molecular inhibitors as targeted therapies for high-risk acute myeloid leukemias	5
Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML)	5
An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency	5
Overexpression of cancerous inhibitor ofPP2A (CIP2A) in acute myeloid leukemia	5
Current status of drug repositioning in hematology	5
Managing complications secondary to Waldenström’s macroglobulinemia	5
New approaches to managing relapsed/refractory Hodgkin lymphoma: the role of checkpoint inhibitors and beyond	5
Systematic review of costs and cost-effectiveness of treatment for relapsed/refractory acute leukemia in children and young adults	5
Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma	5
How can we assess and measure prognosis for MALT lymphoma? A review of current findings and strategies	5
Genome- and transcriptome-wide association studies show that pulmonary embolism is associated with bone-forming proteins	5
Immune thrombocytopenia	5
Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach following H. pylori treatment?	5
Intra-articular injection of platelet-rich plasma in patients with hemophilia and painful knee joint cartilage degeneration	5
Challenges and emerging therapeutic strategies for TP53-mutated acute myeloid leukemia: still disappointing findings?	5
Foreword: a special focus on bleeding disorders	5
A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma	5
¹⁸ F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study	4
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations	4
The role of interleukin-20 and vascular endothelial growth factor-A biomarkers in the detection of renal impairment in patients with multiple myeloma	4
Targeting von Willebrand disease: the current status and future directions of management therapies	4
A review of prophylactic regimens to prevent invasive fungal infections in hematology patients undergoing chemotherapy or stem cell transplantation	4
Late effects of hemopoietic stem cell transplant for sickle cell disease: monitoring and management	4
Development of CD30 CAR-T cells in refractory or relapsed Hodgkin’s lymphoma	4
Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective	4
Screening and interventional strategies for the late effects and toxicities of hematological malignancy treatments in pediatric survivors	4
BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia	4
Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?	4
Hemophilic arthropathy: how to diagnose subclinical bleeding early and how to orthopedically treat a damaged joint	4
A critical evaluation of crizanlizumab for the treatment of sickle cell disease	4
Trend of fluctuations of antithrombin in plasma of patients with COVID-19: a meta-analysis and systematic review	4
Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B	4
Early diagnosis of persons with von Willebrand disease using a machine learning algorithm and real-world data	4
Challenges in the diagnosis of thrombotic thrombocytopenic purpura	4
Interleukin-37, vascular endothelial growth factor A, and transforming growth factor-β1: promising biomarkers in primary immune thrombocytopenia	4
Reduction of ristocetin-induced platelet aggregation (RIPA) during storage despite plasma renewal: evidence for hemostatic importance of GPIbα shedding	4
A comprehensive review on gelatinous transformation of the bone marrow	4
Rational hemostatic management in cirrhosis: from old paradigms to new clinical challenges	4
The medication usage pattern and prevalence of polypharmacy among patients with sickle cell disease: a population-based study in southern Iran	4
Outcome measures in hemophilia: current and future perspectives	4